In a Phase I expansion study investigating the use of ivosidenib monotherapy in 125 R/R IDH1-mutated AML patients (NCT02074839), the CR rate was 21.6% and the median duration of complete remission was 9.3 months22. The gene discussed is IDH1; the disease is acute myeloid leukemia.